格隆汇8月1日丨根据联交所最新权益披露资料显示，2025年7月30日，凯莱英(06821.HK)遭Norges Bank在场内以每股均价112.8016港元减持7.96万股，涉资 约897.9万港元。 减持后，Norges Bank最新持股数目为270.64万股，持股比例由10.11%下降至9.82%。 | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | ( % ) | | CS20250731E00342 | Norges Bank | 1201(L) | | 79.600(L) | HKD 112.8016 | 2.706.400(L) | 9.82(L)30/07/2025 | | 股份代號: | 068 ...

智通财经APP获悉，香港联交所最新资料显示，7月30日，Norges Bank减持凯莱英(06821)7.96万股，每 股作价112.8016港元，总金额约为897.9万港元。减持后最新持股数目为270.64万股，最新持股比例为 9.82%。 ...

香港联交所最新资料显示，7月30日，Norges Bank减持凯莱英（002821）(06821)7.96万股，每股作价 112.8016港元，总金额约为897.9万港元。减持后最新持股数目为270.64万股，最新持股比例为9.82%。 ...

7月30日，三大指数涨跌不一，截至收盘，沪指涨0.17%，深成指跌0.77%，创业板跌1.62%，科创50指数跌1.11%，两市超1600只个股上涨，沪深两市今日成 交额约1.84万亿元。 影视板块表现出众，堪称今日最靓的仔，其中，幸福蓝海（300528.SZ）涨停20%，该公司5天内录得4个大号涨停板，累计上涨113%。此外，慈文传媒 （002343.SZ）、金逸影视（002905.SZ）涨10%，北京文化（000802.SZ）涨超9%。 据悉，幸福蓝海参与出品的影片《南京照相馆》，上映后连续多日蝉联票房冠军。灯塔专业版数据显示，上映6天以来，《南京照相馆》累计录得票房6.61 亿元（截至7月30日上午10时），观影总人次超1800万。其中，该片7月27日的票房为1.46亿元，这也打破了过去3年暑期档历史片单日票房纪录。 创新药持续活跃，辰欣药业（603367.SH）、东诚药业（002675.SZ）涨10%，华润双鹤（600062.SH）、浙江医药（600216.SH）、康辰药业（603590.SH） 均大涨。 中信证券研报称，目前创新药行业已经完成底部夯实，进入到真正的"临床价值重估"阶段，产业估值逻辑正 ...

| 688120 | 华海清 | 5 | 1.08 | 4.02 | 5.15 | | --- | --- | --- | --- | --- | --- | | | 科 | | | | | | 300203 | 聚光科 | 6 | 0.99 | 4.90 | 6.41 | | | 技 | | | | | | 688503 | 聚和材 | 5 | 0.98 | 5.57 | 9.57 | | | 料 | | | | | | 600730 | 中国高 | 5 | 0.95 | 7.96 | 16.52 | | | 科 | | | | | | 300870 | 欧陆通 | 5 | 0.90 | 3.85 | 3.84 | | 600038 | 中直股 | 5 | 0.85 | 4.87 | 1.76 | | | 份 | | | | | | 002637 | 赞宇科 | 5 | 0.84 | 5.61 | 7.78 | | | 技 | | | | | | | 申菱环 | | | | | | 301018 | 境 | 5 | 0.80 | 4.91 | 9.67 | | 000708 | 中信特 | 5 | 0.75 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Core Viewpoint - The CXO (Contract Research Organization) sector is experiencing a significant performance improvement, driven by favorable policies and increased demand for innovative drug development in China [1][4]. Group 1: Industry Performance - CXO concept stocks have shown strong activity, with companies like Boteng Co. rising nearly 10% and others like Kanglong Chemical and Yiqiao Shenzhou increasing over 5% [1]. - WuXi AppTec and Boteng Co. have reported mid-year performance forecasts that confirm the trend of improving performance in CXO companies, indicating a potential reversal in industry prosperity [1][2]. - The overall order volume in the CXO industry has shown positive growth, with KaiLaiYing reporting a 20% increase in new orders for 2024 and Kanglong Chemical's laboratory services seeing over 15% growth [3]. Group 2: Company-Specific Insights - WuXi AppTec expects to achieve approximately 20.64% revenue growth year-on-year for the first half of 2025, with adjusted net profit expected to grow by 44.43% [2]. - Boteng Co. anticipates a revenue increase of 15% to 20% for the first half of 2025, marking a significant turnaround to profitability [2][3]. - The improvement in Boteng Co.'s gross margin and overall profitability is attributed to strict cost control and enhanced operational efficiency [3]. Group 3: Market Trends and Valuation - The CXO sector is poised for a "Davis Double Play," where both profitability and valuation are expected to rise simultaneously due to improved demand and a recovering investment environment [4]. - The current valuation of the CXO sector is at a mid-low level compared to historical highs, suggesting potential for upward movement as the market stabilizes [4]. - Analysts predict that the demand for innovative drug development will continue to grow, particularly in the context of new technologies like ADCs (Antibody-Drug Conjugates) [5].

Group 1 - The core viewpoint of the articles highlights the active performance of innovative drug stocks in the Hong Kong market, with the Hong Kong Innovative Drug 50 ETF (513780) rising over 87% year-to-date and experiencing significant net inflows since June [1][2] - Key individual stocks such as Kailaiying, CanSino Biologics, and others have shown substantial gains, indicating strong investor interest and confidence in the sector [1] - The National Healthcare Security Administration has initiated the 11th batch of centralized procurement, optimizing selection rules to ensure fair pricing and cost coverage for selected enterprises, which may positively impact the innovative drug market [1][2] Group 2 - Guosen Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with recent adjustments to the medical insurance catalog providing economic support for innovative drug development [2] - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 69.16% of the index, including high-quality A-share companies involved in drug research and development [2] - The innovative drug sector is positioned at a new historical starting point, with domestic companies enhancing competitiveness and expanding overseas, supported by rapid revenue growth and favorable policies [2]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETFs, with Tianhong Innovative Drug ETF (517380) leading the industry with a 1.89% increase and a total trading volume of 4.6489 million yuan on July 23, 2025 [2] - The Tianhong Innovative Drug ETF has seen a cumulative increase of 3.93% over the past week, indicating positive momentum in the sector [2] - The Biopharmaceutical ETF (159859) also showed a 1.50% increase with a trading volume of 40.8703 million yuan, reflecting strong investor interest [2] Group 2 - The Biopharmaceutical ETF (159859) has achieved a 2.84% increase over the past week, ranking first among comparable funds, with an average daily trading volume of 110 million yuan [3] - The Biopharmaceutical ETF has experienced a significant growth of 543 million yuan in scale over the past year, indicating robust demand [3] - Guotai Junan Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with new insurance directories supporting innovative drug development [3] Group 3 - The collaboration between stable operation of medical insurance funds and optimized centralized procurement policies is positively impacting the innovative drug industry, enhancing patient accessibility and market demand [4] - Recent trends show that multiple pharmaceutical companies are successfully launching innovative drugs overseas, validating China's R&D capabilities [4] - The Tianhong Innovative Drug ETF (517380) is noted as the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Select 50 Index, providing comprehensive coverage of A-shares and Hong Kong stocks [4]

Meeting Overview - The company will hold the 2025 Second Extraordinary General Meeting and the 2025 Third A-share and H-share General Meetings on August 6, 2025 [1][2] - The on-site meeting will start at 14:00, with network voting available from 9:15 to 15:00 on the same day [1][2] Voting Procedures - Shareholders can vote either in person or through authorized representatives, with specific voting methods outlined for A-share and H-share shareholders [2][3] - A-share shareholders participating in network voting will have their votes considered for both the Second Extraordinary General Meeting and the Third A-share General Meeting [2][3] Agenda Items - The agenda for the Second Extraordinary General Meeting includes proposals for amending the company's independent non-executive director work system and related management rules, as well as changes to fundraising purposes and project investments [5][6] - The Third A-share General Meeting will also address similar proposals, with specific items requiring a two-thirds majority for approval [6][7] Attendance Registration - Shareholders must register for the meeting, providing necessary identification and documentation, with specific instructions for both individual and corporate shareholders [9][10] - Registration can also be done via mail or email for remote shareholders, with a deadline set for July 31, 2025 [9][10] Contact Information - The company has provided contact details for inquiries related to the meetings, including a phone number and email address [9]